Annual CFO
-$161.90 M
-$73.05 M-82.21%
December 31, 2023
Summary
- As of February 7, 2025, LXRX annual cash flow from operations is -$161.90 million, with the most recent change of -$73.05 million (-82.21%) on December 31, 2023.
- During the last 3 years, LXRX annual CFO has fallen by -$18.93 million (-13.24%).
- LXRX annual CFO is now -187.62% below its all-time high of $184.78 million, reached on December 31, 2015.
Performance
LXRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$53.62 M
-$5.08 M-10.46%
September 30, 2024
Summary
- As of February 7, 2025, LXRX quarterly cash flow from operations is -$53.62 million, with the most recent change of -$5.08 million (-10.46%) on September 30, 2024.
- Over the past year, LXRX quarterly CFO has increased by +$1.51 million (+2.74%).
- LXRX quarterly CFO is now -120.16% below its all-time high of $265.92 million, reached on December 31, 2015.
Performance
LXRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$207.84 M
-$12.00 M-6.13%
September 30, 2024
Summary
- As of February 7, 2025, LXRX TTM cash flow from operations is -$207.84 million, with the most recent change of -$12.00 million (-6.13%) on September 30, 2024.
- Over the past year, LXRX TTM CFO has dropped by -$22.42 million (-12.09%).
- LXRX TTM CFO is now -212.48% below its all-time high of $184.78 million, reached on December 31, 2015.
Performance
LXRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
LXRX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -82.2% | +2.7% | -12.1% |
| 3 y3 years | -13.2% | -175.8% | -130.7% |
| 5 y5 years | -8.9% | -128.1% | -282.6% |
LXRX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -86.0% | at low | -175.8% | +2.7% | -143.7% | at low |
| 5 y | 5-year | -242.3% | at low | -212.7% | +2.7% | -277.1% | at low |
| alltime | all time | -187.6% | +12.7% | -120.2% | +37.3% | -212.5% | +4.4% |
Lexicon Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$53.62 M(+10.5%) | -$207.84 M(+6.1%) |
| Jun 2024 | - | -$48.54 M(-12.0%) | -$195.84 M(+5.6%) |
| Mar 2024 | - | -$55.13 M(+9.1%) | -$185.41 M(+14.5%) |
| Dec 2023 | -$161.90 M(+82.2%) | -$50.55 M(+21.5%) | -$161.90 M(+21.8%) |
| Sep 2023 | - | -$41.62 M(+9.2%) | -$132.92 M(+20.0%) |
| Jun 2023 | - | -$38.12 M(+20.6%) | -$110.74 M(+14.1%) |
| Mar 2023 | - | -$31.61 M(+46.6%) | -$97.04 M(+9.2%) |
| Dec 2022 | -$88.85 M(+2.1%) | -$21.57 M(+11.0%) | -$88.85 M(-1.4%) |
| Sep 2022 | - | -$19.44 M(-20.4%) | -$90.11 M(+2.6%) |
| Jun 2022 | - | -$24.42 M(+4.3%) | -$87.82 M(+3.0%) |
| Mar 2022 | - | -$23.42 M(+2.6%) | -$85.28 M(-2.0%) |
| Dec 2021 | -$87.02 M(-39.1%) | -$22.83 M(+33.1%) | -$87.02 M(-11.6%) |
| Sep 2021 | - | -$17.15 M(-21.6%) | -$98.43 M(-19.1%) |
| Jun 2021 | - | -$21.88 M(-13.0%) | -$121.66 M(-16.7%) |
| Mar 2021 | - | -$25.16 M(-26.5%) | -$146.07 M(+2.2%) |
| Dec 2020 | -$142.97 M(-225.6%) | -$34.24 M(-15.2%) | -$142.97 M(+7.4%) |
| Sep 2020 | - | -$40.38 M(-12.8%) | -$133.10 M(-235.9%) |
| Jun 2020 | - | -$46.30 M(+109.9%) | $97.97 M(-16.5%) |
| Mar 2020 | - | -$22.05 M(-9.5%) | $117.37 M(+3.1%) |
| Dec 2019 | $113.81 M(-176.6%) | -$24.37 M(-112.8%) | $113.81 M(+2.5%) |
| Sep 2019 | - | $190.70 M(-808.9%) | $111.05 M(-209.1%) |
| Jun 2019 | - | -$26.90 M(+5.0%) | -$101.83 M(-20.1%) |
| Mar 2019 | - | -$25.62 M(-5.6%) | -$127.45 M(-14.2%) |
| Dec 2018 | -$148.61 M(-19.8%) | -$27.13 M(+22.3%) | -$148.61 M(-4.2%) |
| Sep 2018 | - | -$22.18 M(-57.8%) | -$155.19 M(-7.1%) |
| Jun 2018 | - | -$52.52 M(+12.3%) | -$166.97 M(+13.8%) |
| Mar 2018 | - | -$46.77 M(+38.8%) | -$146.67 M(-20.9%) |
| Dec 2017 | -$185.39 M(+5.6%) | -$33.71 M(-0.7%) | -$185.39 M(-7.5%) |
| Sep 2017 | - | -$33.96 M(+5.4%) | -$200.47 M(-0.6%) |
| Jun 2017 | - | -$32.23 M(-62.3%) | -$201.73 M(-7.2%) |
| Mar 2017 | - | -$85.50 M(+75.2%) | -$217.38 M(+23.8%) |
| Dec 2016 | -$175.63 M(-195.0%) | -$48.79 M(+38.5%) | -$175.63 M(-226.3%) |
| Sep 2016 | - | -$35.22 M(-26.4%) | $139.09 M(-6.5%) |
| Jun 2016 | - | -$47.88 M(+9.5%) | $148.82 M(-9.5%) |
| Mar 2016 | - | -$43.74 M(-116.4%) | $164.52 M(-11.0%) |
| Dec 2015 | $184.78 M(-344.3%) | $265.92 M(-1143.5%) | $184.78 M(-315.8%) |
| Sep 2015 | - | -$25.48 M(-20.8%) | -$85.61 M(+5.3%) |
| Jun 2015 | - | -$32.18 M(+37.0%) | -$81.31 M(+18.2%) |
| Mar 2015 | - | -$23.48 M(+426.8%) | -$68.79 M(-9.0%) |
| Dec 2014 | -$75.62 M(-17.0%) | -$4.46 M(-79.0%) | -$75.62 M(-18.6%) |
| Sep 2014 | - | -$21.19 M(+7.8%) | -$92.91 M(-2.9%) |
| Jun 2014 | - | -$19.66 M(-35.2%) | -$95.65 M(-1.5%) |
| Mar 2014 | - | -$30.32 M(+39.5%) | -$97.13 M(+6.6%) |
| Dec 2013 | -$91.08 M(-3.6%) | -$21.74 M(-9.2%) | -$91.08 M(+1.5%) |
| Sep 2013 | - | -$23.93 M(+13.3%) | -$89.77 M(-1.2%) |
| Jun 2013 | - | -$21.13 M(-12.9%) | -$90.90 M(-0.9%) |
| Mar 2013 | - | -$24.27 M(+18.8%) | -$91.73 M(-2.9%) |
| Dec 2012 | -$94.46 M | -$20.43 M(-18.5%) | -$94.46 M(-2.1%) |
| Sep 2012 | - | -$25.07 M(+14.2%) | -$96.52 M(+5.3%) |
| Jun 2012 | - | -$21.96 M(-18.7%) | -$91.67 M(-1.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$27.00 M(+20.1%) | -$93.40 M(+6.2%) |
| Dec 2011 | -$87.94 M(+6.8%) | -$22.49 M(+11.2%) | -$87.94 M(+3.6%) |
| Sep 2011 | - | -$20.22 M(-14.7%) | -$84.86 M(+1.9%) |
| Jun 2011 | - | -$23.69 M(+10.0%) | -$83.27 M(+1.3%) |
| Mar 2011 | - | -$21.54 M(+11.0%) | -$82.21 M(-0.2%) |
| Dec 2010 | -$82.37 M(-7.5%) | -$19.41 M(+4.2%) | -$82.37 M(+2.7%) |
| Sep 2010 | - | -$18.63 M(-17.6%) | -$80.21 M(-1.3%) |
| Jun 2010 | - | -$22.62 M(+4.3%) | -$81.26 M(-1.6%) |
| Mar 2010 | - | -$21.70 M(+25.8%) | -$82.56 M(-7.3%) |
| Dec 2009 | -$89.02 M(-6.9%) | -$17.25 M(-12.4%) | -$89.02 M(-2.7%) |
| Sep 2009 | - | -$19.68 M(-17.7%) | -$91.45 M(-3.2%) |
| Jun 2009 | - | -$23.93 M(-15.0%) | -$94.48 M(-2.8%) |
| Mar 2009 | - | -$28.15 M(+43.0%) | -$97.20 M(+1.7%) |
| Dec 2008 | -$95.60 M(+28.6%) | -$19.69 M(-13.3%) | -$95.60 M(+6.0%) |
| Sep 2008 | - | -$22.71 M(-14.8%) | -$90.22 M(+4.7%) |
| Jun 2008 | - | -$26.65 M(+0.4%) | -$86.18 M(+7.6%) |
| Mar 2008 | - | -$26.55 M(+85.5%) | -$80.06 M(+7.7%) |
| Dec 2007 | -$74.32 M(+30.6%) | -$14.31 M(-23.3%) | -$74.32 M(+6.3%) |
| Sep 2007 | - | -$18.66 M(-9.1%) | -$69.94 M(+5.4%) |
| Jun 2007 | - | -$20.53 M(-1.4%) | -$66.37 M(+0.1%) |
| Mar 2007 | - | -$20.82 M(+109.6%) | -$66.28 M(+16.5%) |
| Dec 2006 | -$56.91 M(-342.8%) | -$9.93 M(-34.2%) | -$56.91 M(+60.4%) |
| Sep 2006 | - | -$15.09 M(-26.2%) | -$35.49 M(>+9900.0%) |
| Jun 2006 | - | -$20.44 M(+78.6%) | -$283.00 K(-101.1%) |
| Mar 2006 | - | -$11.45 M(-199.6%) | $25.67 M(+9.5%) |
| Dec 2005 | $23.44 M(-155.5%) | $11.49 M(-42.9%) | $23.44 M(+242.1%) |
| Sep 2005 | - | $20.12 M(+265.1%) | $6.85 M(-141.2%) |
| Jun 2005 | - | $5.51 M(-140.3%) | -$16.64 M(-58.9%) |
| Mar 2005 | - | -$13.68 M(+168.1%) | -$40.44 M(-4.3%) |
| Dec 2004 | -$42.26 M(+447.6%) | -$5.10 M(+51.1%) | -$42.26 M(+383.3%) |
| Sep 2004 | - | -$3.38 M(-81.5%) | -$8.74 M(-45.5%) |
| Jun 2004 | - | -$18.29 M(+18.1%) | -$16.05 M(+91.8%) |
| Mar 2004 | - | -$15.49 M(-154.5%) | -$8.37 M(+8.4%) |
| Dec 2003 | -$7.72 M(-73.2%) | $28.41 M(-366.1%) | -$7.72 M(-76.6%) |
| Sep 2003 | - | -$10.68 M(+0.6%) | -$32.92 M(-6.0%) |
| Jun 2003 | - | -$10.61 M(-28.5%) | -$35.04 M(+1.9%) |
| Mar 2003 | - | -$14.84 M(-562.8%) | -$34.40 M(+19.5%) |
| Dec 2002 | -$28.79 M(+60.0%) | $3.21 M(-125.1%) | -$28.79 M(-18.1%) |
| Sep 2002 | - | -$12.79 M(+28.3%) | -$35.18 M(+45.5%) |
| Jun 2002 | - | -$9.97 M(+8.0%) | -$24.18 M(+25.7%) |
| Mar 2002 | - | -$9.23 M(+190.4%) | -$19.25 M(+7.0%) |
| Dec 2001 | -$17.99 M(+1097.7%) | -$3.18 M(+76.4%) | -$17.99 M(+20.1%) |
| Sep 2001 | - | -$1.80 M(-64.2%) | -$14.98 M(-0.5%) |
| Jun 2001 | - | -$5.03 M(-36.9%) | -$15.06 M(+42.1%) |
| Mar 2001 | - | -$7.97 M(+4666.5%) | -$10.59 M(+605.3%) |
| Dec 2000 | -$1.50 M(-84.4%) | -$167.30 K(-91.1%) | -$1.50 M(+12.5%) |
| Sep 2000 | - | -$1.88 M(+228.8%) | -$1.33 M(-344.8%) |
| Jun 2000 | - | -$571.80 K(-151.2%) | $545.20 K(-51.2%) |
| Mar 2000 | - | $1.12 M | $1.12 M |
| Dec 1999 | -$9.60 M | - | - |
FAQ
- What is Lexicon Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals annual CFO year-on-year change?
- What is Lexicon Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals quarterly CFO year-on-year change?
- What is Lexicon Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals TTM CFO year-on-year change?
What is Lexicon Pharmaceuticals annual cash flow from operations?
The current annual CFO of LXRX is -$161.90 M
What is the all time high annual CFO for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high annual cash flow from operations is $184.78 M
What is Lexicon Pharmaceuticals annual CFO year-on-year change?
Over the past year, LXRX annual cash flow from operations has changed by -$73.05 M (-82.21%)
What is Lexicon Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of LXRX is -$53.62 M
What is the all time high quarterly CFO for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high quarterly cash flow from operations is $265.92 M
What is Lexicon Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, LXRX quarterly cash flow from operations has changed by +$1.51 M (+2.74%)
What is Lexicon Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of LXRX is -$207.84 M
What is the all time high TTM CFO for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high TTM cash flow from operations is $184.78 M
What is Lexicon Pharmaceuticals TTM CFO year-on-year change?
Over the past year, LXRX TTM cash flow from operations has changed by -$22.42 M (-12.09%)